Digital Health Global
SEPTEMBER 28, 2023
Investments will focus on the next generation of pharma R&D to accelerate drug development, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.
Digital Health Global
JANUARY 31, 2024
In a large, bi-annual survey on patient experiences with clinical research, use of electronic consent forms (on an iPad, tablet, or other device) increased from 24% in 2019 to 44% in 2021, dipping slightly in 2023 to 32%. Medable, which ranked in the top 8% of software companies on the 2023 Inc. in Phase 3.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
American Well
JANUARY 29, 2020
Disease Origin and Spread : The new coronavirus (2019-nCOV) was first identified in December 2019 as the cause of an outbreak of respiratory illness in the city of Wuhan, Hubei Province, China. Since that time Chinese health officials have reported hundreds of cases in the city of Wuhan, some causing severe illness or death.
American Well
JANUARY 29, 2020
Disease Origin and Spread : The new coronavirus (2019-nCOV) was first identified in December 2019 as the cause of an outbreak of respiratory illness in the city of Wuhan, Hubei Province, China. Since that time Chinese health officials have reported hundreds of cases in the city of Wuhan, some causing severe illness or death.
Lloyd Price
DECEMBER 11, 2023
The exhilarating pace of change is evidenced at Cera, a digital-first home healthcare enterprise that has seen the patient visits that drive its processes increase from 120,000 in 2019 to 18 million in 2023. Digital health companies can help identify new drug targets, design clinical trials and analyse data more effectively.
Lloyd Price
JUNE 17, 2023
Livongo went public in 2019 and was acquired by Teladoc in 2020. 2019: Livongo goes public on the NYSE. 2019: Livongo goes public on the NYSE. As the ability to collect and analyze large amounts of patient data grows, there is a growing opportunity for companies to develop personalized treatments and care plans.
Lloyd Price
NOVEMBER 21, 2018
In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals. Novartis said earlier this month that it was on track for a launch in the first half of 2019.
Expert insights. Personalized for you.
88 
Let's personalize your content